<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A24FD58-D7D3-418E-BE01-3425AD8F9D43"><gtr:id>5A24FD58-D7D3-418E-BE01-3425AD8F9D43</gtr:id><gtr:name>Telethon Kids Institute</gtr:name><gtr:address><gtr:line1>P.O. Box 855</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/01AEF29D-5736-40A4-9696-D937C956417B"><gtr:id>01AEF29D-5736-40A4-9696-D937C956417B</gtr:id><gtr:name>Stallergenes</gtr:name><gtr:address><gtr:line1>Stallergenes</gtr:line1><gtr:line2>6, rue Alexis de Tocqueville</gtr:line2><gtr:line3>ANTONY</gtr:line3><gtr:postCode>92160</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CA10F5D0-8E26-4790-BF21-025009DDA322"><gtr:id>CA10F5D0-8E26-4790-BF21-025009DDA322</gtr:id><gtr:name>Medical University of Graz</gtr:name><gtr:address><gtr:line1>Harrachgasse 21</gtr:line1><gtr:line4>Graz</gtr:line4><gtr:line5>A-8010</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Austria</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A24FD58-D7D3-418E-BE01-3425AD8F9D43"><gtr:id>5A24FD58-D7D3-418E-BE01-3425AD8F9D43</gtr:id><gtr:name>Telethon Kids Institute</gtr:name><gtr:address><gtr:line1>P.O. Box 855</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/01AEF29D-5736-40A4-9696-D937C956417B"><gtr:id>01AEF29D-5736-40A4-9696-D937C956417B</gtr:id><gtr:name>Stallergenes</gtr:name><gtr:address><gtr:line1>Stallergenes</gtr:line1><gtr:line2>6, rue Alexis de Tocqueville</gtr:line2><gtr:line3>ANTONY</gtr:line3><gtr:postCode>92160</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CA10F5D0-8E26-4790-BF21-025009DDA322"><gtr:id>CA10F5D0-8E26-4790-BF21-025009DDA322</gtr:id><gtr:name>Medical University of Graz</gtr:name><gtr:address><gtr:line1>Harrachgasse 21</gtr:line1><gtr:line4>Graz</gtr:line4><gtr:line5>A-8010</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Austria</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/59829DBB-3394-42FF-9E58-58625AC9988C"><gtr:id>59829DBB-3394-42FF-9E58-58625AC9988C</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Francis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/85F4F906-8476-4AEC-9B1B-818D2496249B"><gtr:id>85F4F906-8476-4AEC-9B1B-818D2496249B</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>Durham</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601303"><gtr:id>D59E0B23-A24D-4551-88FA-842F31FA1BE9</gtr:id><gtr:title>A novel serum-based assay of functional IgG inhibitory activity is predictive of the clinical response to immunotherapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601303</gtr:grantReference><gtr:abstractText>Hayfever affects 12 million people in UK and may ruin what for most of us is the best time of the year. Hayfever impairs concentration at work and may reduce performance in school exams. Many sufferers respond to antihistamines and nasal steroid sprays. There remains a hard core who may benefit from allergy vaccination (desensitisation injections). Discovered in UK 100 years ago, this treatment is highly effective but requires specialist supervision . We have developed in partnership with a company, ALK Abello, an alternative, effective and safer vaccine containing grass extract that is taken daily as a rapidly dissolving tablet under the tongue (GRAZAX). Based on our understanding of how vaccination works, we now wish to develop a test that measures ?protective? antibodies in the bloodstream that will allow us to predict those patients who are likely to respond best to desensitisation and to monitor the effects of treatment.</gtr:abstractText><gtr:technicalSummary>Hayfever affects 12 million people in UK, of whom 4 million remain uncontrolled by medical therapy. For such individuals, subcutaneous allergen immunotherapy is effective and involves weekly then monthly injections of grass pollen extract, usually continued for 3-4 years. The subcutaneous route is associated with a small risk of systemic reactions and requires specialist supervision. The alternative sublingual route, using high dose allergen in liquid/tablet form under the tongue, is also effective and safe for home use. We are currently undertaking a definitive 5 year trial to address whether sublingual immunotherapy, like subcutaneous treatment, induces long-term remission after 3 years therapy.
Immunotherapy deviates B cell responses towards production of allergen-specific IgG, particularly IgG4, which has the potential to block IgE-mediated responses. Although IgG4 levels have historically shown poor correlations with treatment response, ?functional? assays reflecting antibody avidity/affinity could be more predictive of efficacy. Pollen-specific IgG4 induced by immunotherapy inhibits IgE-facilitated allergen presentation (IgE-FAP), possibly a rate-limiting process in Th2 cell-driven allergic responses at the low allergen concentrations encountered during the pollen season. We have replaced this complex technique with a simple flow cytometric assay (IgE-FAB) detecting allergen-IgE complex binding to B cells expressing CD23 (low affinity IgE receptor). Binding is inhibited by IgG within sera of immunotherapy-treated subjects. Remarkably, in a small double-blind withdrawal trial of immunotherapy, continuing clinical remission was associated with persistence of IgE-FAB inhibitory activity despite a marked reversal of absolute IgG4 concentrations. Thus our ?functional? assay is distinct from serum IgG as detected by ELISA. The detailed technical validation of this assay is now published (Dec 06). 

We are now seeking validation of this assay as a biomarker in a wider context. Inhibitory activity for IgE-FAB will be measured in 2 recent large multi-centre immunotherapy trials in severe hayfever: (1) the UK Subcutaneous Immunotherapy study (n=410) - a one year double-blind placebo-controlled dose-response study, and (2) the International Sublingual Immunotherapy study (n=634) - an ongoing 5 year double-blind placebo-controlled study of sublingual grass allergen tablets, with the final 2 years comprising a double-blind withdrawal of therapy. Published results for year one confirm good efficacy. 
These definitive studies will help determine whether simple immunoreactive IgG or ?functional? IgG are predictive biomarkers of the clinical response in individual patients. Moreover, we aim to provide the basis for a predictive assay to identify the responder population, when to discontinue therapy and to predict relapse after treatment discontinuation.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>179981</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stallergenes</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Inhibition of IgE-facilitated allergen binding following mix grass pollen specific sublingual immunotherapy</gtr:description><gtr:id>D0ADED1F-DF48-4FE2-8A34-871C1C670CB0</gtr:id><gtr:impact>We look forward to a joint publication</gtr:impact><gtr:outcomeId>ioUtUhmzP7r-1</gtr:outcomeId><gtr:partnerContribution>All laboratory analyses will be perfomed by research team. We look forward to a joint publication</gtr:partnerContribution><gtr:piContribution>Principle Investigator for this project.
Laboratory experimental analyses and data analysis Samples supplied Stallergenes SA</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Graz</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Department of Paediatrics, Respiratory and Allergic Disease Division</gtr:department><gtr:description>Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children.</gtr:description><gtr:id>CD5D17A0-D1FB-4A7C-A2CB-012D939E0111</gtr:id><gtr:impact>Joint collaboration resulting in publicationTime course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children.


Varga EM, Francis JN, Zach MS, Klunker S, Aberer W, Durham SR. Clin Exp Allergy. 2009;39:1353-7.
PMID: 19538349.
Further recent joint publication on line:
Varga EM, Kausar F, Aberer W, Zach M, Eber E, Durham SR, Shamji MH.Tolerant beekeepers display venom-specific functional IgG(4) antibodies in the absence of specific IgE. J Allergy Clin Immunol. 2012. doi:pii: S0091-6749(12)01452-2. 10.1016/j.jaci.2012.08.037. [Epub ahead of print] 


PMID: 23063581</gtr:impact><gtr:outcomeId>LfQGjXatpFY-1</gtr:outcomeId><gtr:partnerContribution>Joint collaboration resulting in publication in journal of Clinical and Experimental Allergy 2009</gtr:partnerContribution><gtr:piContribution>Principle Investigator for this project.
Laboratory experimental analyses and data analysis Samples supplied Dr Eva-Maria Varga</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Vienna</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Laboratory for Allergy Research Vienna</gtr:department><gtr:description>Bio-assay of serum pre/post recombinant birch immunotherapy</gtr:description><gtr:id>C6E70E40-1AC4-4337-8701-8985961D2747</gtr:id><gtr:impact>Joint collaboration resulting in publication 
Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010;40:1346-52.PMID: 20604801

Further Joint publication :
Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji M, Layhadi J, Gieras A, Swoboda I, Zafred D?, Keller, Valent P, Durham S Valenta R. A non-allergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG towards IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. Journal of Immunology 2012 (favourably reviewed in final revision)</gtr:impact><gtr:outcomeId>WEZ9gVj2i6F-1</gtr:outcomeId><gtr:partnerContribution>Joint collaboration resulting in publication:</gtr:partnerContribution><gtr:piContribution>Principle Investigator for this project.
Laboratory experimental analyses and data analysis Samples supplied Profesor Rudolf Valenta</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Telethon Kids Institute</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>IgG modulation of IgE-associated risk for wheeze in high risk (mite sensitised) children: a potential predictive bioassay</gtr:description><gtr:id>67B33520-4DE8-4034-A12A-EF6E545484FB</gtr:id><gtr:impact>We look forward to a joint publication</gtr:impact><gtr:outcomeId>pv9YtMj3jkX-1</gtr:outcomeId><gtr:partnerContribution>We look forward to a joint publication</gtr:partnerContribution><gtr:piContribution>Principle Investigator for this project.
Laboratory experimental analyses and data analysis Samples supplied Profesor Patrik Holt</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D780869D-C6EE-40B5-9434-49EEF3C6E972</gtr:id><gtr:impact>Wellcome-funded public engagement at King's Mall, Hammersmith Shopping Centre. 'Heart and Lung Convenience Store'. 10-15 participants engaged on hayfever its importance, diagnosis and management with skin prick testing demonstration with active participation of attendees.</gtr:impact><gtr:outcomeId>56bcbab34f98b6.84129015</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www1.imperial.ac.uk/nhli/public_engagement/the_curious_act/the_heart_and_lung_convenience_store/</gtr:url><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio broadcast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7778A20C-035E-47DF-AC7E-C31A2050A9D0</gtr:id><gtr:impact>BBC radio broadcast to highlight importance of insect venom anaphylaxis, diagnosis and its treatment with immunotherapy</gtr:impact><gtr:outcomeId>56bcb8451d2ba8.34844931</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Television interview</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>640F0E00-DC63-4251-B23E-E3FB881BDDDF</gtr:id><gtr:impact>Broadcast on 6 O clock national television news

Enquiries from members of public</gtr:impact><gtr:outcomeId>qKfDrAsZQZC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>497124</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigator initiated grant:Regeneron Pharmaceuticals Inc</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Regeneron Pharmaceuticals, Inc.</gtr:fundingOrg><gtr:fundingRef>REGN1908/1909</gtr:fundingRef><gtr:id>07CF09AA-83BF-4B8A-9F9F-087B492CE7E4</gtr:id><gtr:outcomeId>5464cd48197413.20284083</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3800000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Immune Tolerance Network Clinical Trial Application (Single Centre award)</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>ITN049D</gtr:fundingRef><gtr:id>E096924F-2179-489A-B21E-53180BB949F7</gtr:id><gtr:outcomeId>L6kJbrEHSqE0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>54468</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigator-initiated project grant: Biotech Tools</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>BioTech Tools</gtr:fundingOrg><gtr:id>C394540C-E3D1-44A4-8257-4CB3C4616B38</gtr:id><gtr:outcomeId>5464cc9214b894.64692775</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>330000</gtr:amountPounds><gtr:country>Denmark, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigator-led collaboration with ALK Denmark, a manufacturer of allergy vaccines</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>ALK-Abell? A/S</gtr:fundingOrg><gtr:id>65BB4A36-A922-4AB4-B8AB-85A7E37DC20F</gtr:id><gtr:outcomeId>5464ba2b0c9ae7.28374595</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>211393</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Immne Tolerance Network</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:fundingOrg><gtr:fundingRef>FY15ITN086, A3</gtr:fundingRef><gtr:id>B79E42A3-09B0-4CF6-A944-60B8918E3795</gtr:id><gtr:outcomeId>56bcbbc85fec38.79466649</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55782</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigator initiated project grant: Merck</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>809C870B-A579-4190-8B91-2674DA67B021</gtr:id><gtr:outcomeId>5464cc2501e2e6.42395641</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>New registration for hay fever vaccine in USA 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>9ED5C3AA-0FD6-4E4C-9D4A-E005CB7FC467</gtr:id><gtr:impact>Sublingual tablet immunotherapy is an effective, safer alternative to subcutaneous immunotherapy that induces long-term disease remission. The tablet approach is now widespread in Europe and is being successfully extended to other allergies (housedust mite) and internationally (ragweed allergy in USA and Japanese Cedar pollen allergy). The work is quoted in guidelines internationally and regulatory bodies now recognise the disease-modifying potential of immunotherapy and its ability to induce long-term remission.</gtr:impact><gtr:outcomeId>5464c0565a1d66.45377250</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.fda.gov/BiologicsBloodVaccines/Allergenics/ucm393162</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A bioassay for measuring functional activity of IgG-containing serum obtained pre/post immunotherapy.</gtr:description><gtr:id>2FDB31A5-16F7-434A-9622-15A46D0A0535</gtr:id><gtr:impact>Method published in J Immunol methods
Potential assay for predicting clinical response to allergen immunotherapy</gtr:impact><gtr:outcomeId>JLwJSzyq9UT</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Assay of binding of allergen-IgE complexes to B cells and its inhibition by IgG-containing serum</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E51C2FD3-7346-4C87-BD0D-6AB5D7A9E9C7</gtr:id><gtr:title>Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c75efd55aa28627eb08d2d4fa7d382f"><gtr:id>5c75efd55aa28627eb08d2d4fa7d382f</gtr:id><gtr:otherNames>Radulovic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>hHLUQG4jG1T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BC5450B-E98D-42DD-BC95-AEBD7C9CF442</gtr:id><gtr:title>Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f75c3ebc74ea287044d5854fdf4f36f"><gtr:id>0f75c3ebc74ea287044d5854fdf4f36f</gtr:id><gtr:otherNames>Rotiroti G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_15138_28_22971521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE0DAA81-DEE7-4939-B83A-2549F9D96B09</gtr:id><gtr:title>Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes.</gtr:title><gtr:parentPublicationTitle>Clinical and translational allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3044ab5d951a1fe9757e8e6f01a15fb"><gtr:id>f3044ab5d951a1fe9757e8e6f01a15fb</gtr:id><gtr:otherNames>Steveling EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-7022</gtr:issn><gtr:outcomeId>56bcb014622196.17064906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D992CF71-C1E0-4D68-B610-92A18DBE87D5</gtr:id><gtr:title>Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e99419069b860ea088ea32ca81cb26b1"><gtr:id>e99419069b860ea088ea32ca81cb26b1</gtr:id><gtr:otherNames>James LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>ACng7jrbnFH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C924151-9F7C-47E5-80CC-4E58029AB680</gtr:id><gtr:title>Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f26da72ee37dfc6742069ea3f6c9aafe"><gtr:id>f26da72ee37dfc6742069ea3f6c9aafe</gtr:id><gtr:otherNames>Varga EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_15138_28_23063581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>617DF99A-A74D-4492-89DA-09358CCED847</gtr:id><gtr:title>Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d266467d73cc84f929d04bffa3f0c2d"><gtr:id>3d266467d73cc84f929d04bffa3f0c2d</gtr:id><gtr:otherNames>Scadding GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>eTZm8JEFAkU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D65A157-881E-4E15-94DE-A101921AA4FF</gtr:id><gtr:title>SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ef542f164b4e5636afc9051893a45c"><gtr:id>91ef542f164b4e5636afc9051893a45c</gtr:id><gtr:otherNames>Durham SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_15138_28_22285278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0037633A-4323-4240-8C6C-3188AB3EE2CB</gtr:id><gtr:title>Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bac79e880b4b18e0e339209f3639c3b0"><gtr:id>bac79e880b4b18e0e339209f3639c3b0</gtr:id><gtr:otherNames>Pree I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>XSf2LJbXAzY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0156544F-EFCC-4846-BB1F-D07E2468BB65</gtr:id><gtr:title>Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/064e2a543a086b4006b8f41af8370273"><gtr:id>064e2a543a086b4006b8f41af8370273</gtr:id><gtr:otherNames>Pilette C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>M9g4Yuzkfiy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F331B1A3-30E7-4F08-BC2B-17D70232F29B</gtr:id><gtr:title>Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/645007b42961157c41cac06c084e35fa"><gtr:id>645007b42961157c41cac06c084e35fa</gtr:id><gtr:otherNames>Klunker S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>VurP5EYPgs1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B11233CE-68AC-4E06-B251-044570A2B325</gtr:id><gtr:title>Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42155163bf591934c05740887828b4ac"><gtr:id>42155163bf591934c05740887828b4ac</gtr:id><gtr:otherNames>Shamji MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5464b4864df3a9.85271906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>854CC2F2-6040-4785-A253-7673B4014389</gtr:id><gtr:title>Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ef542f164b4e5636afc9051893a45c"><gtr:id>91ef542f164b4e5636afc9051893a45c</gtr:id><gtr:otherNames>Durham SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>ZP2Gd2nTMCB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>445E06BA-335D-4924-8561-9BB0AFA1A1F8</gtr:id><gtr:title>Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b4a28a9efea6aa730de4f1c70ba63b4"><gtr:id>0b4a28a9efea6aa730de4f1c70ba63b4</gtr:id><gtr:otherNames>Francis JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>GWhZQ6paN8j</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6329E7A-DCCA-4AAB-9B59-88E9DF0C0068</gtr:id><gtr:title>The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42155163bf591934c05740887828b4ac"><gtr:id>42155163bf591934c05740887828b4ac</gtr:id><gtr:otherNames>Shamji MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>jZNLnXa6KkZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>842079FC-E600-4B8C-8165-0C41B318731C</gtr:id><gtr:title>Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68035d5f0ced0a058aff3dceadb4aaf0"><gtr:id>68035d5f0ced0a058aff3dceadb4aaf0</gtr:id><gtr:otherNames>Vickery BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5464b485f2e113.26353105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09CD7182-CE29-456B-B4CE-7E6DF29D6253</gtr:id><gtr:title>Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ef542f164b4e5636afc9051893a45c"><gtr:id>91ef542f164b4e5636afc9051893a45c</gtr:id><gtr:otherNames>Durham SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>QpUjebVwpWA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4ABAE54-EEA6-4C17-89DE-283A6B11CB8A</gtr:id><gtr:title>Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f26da72ee37dfc6742069ea3f6c9aafe"><gtr:id>f26da72ee37dfc6742069ea3f6c9aafe</gtr:id><gtr:otherNames>Varga EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>JYtvEsNGcA1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A55C646-D0A6-479F-833A-25FC3DB4CEEB</gtr:id><gtr:title>Grass Pollen Immunotherapy Induces an Allergen-Specific IgA2 Antibody Response Associated with Mucosal TGF-&amp;nbsp; Expression</gtr:title><gtr:parentPublicationTitle>The Journal of Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/064e2a543a086b4006b8f41af8370273"><gtr:id>064e2a543a086b4006b8f41af8370273</gtr:id><gtr:otherNames>Pilette C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>5a6f09c70cd5d4.15046988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47CE4690-C529-45EF-8281-796AB89BA73C</gtr:id><gtr:title>Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e99419069b860ea088ea32ca81cb26b1"><gtr:id>e99419069b860ea088ea32ca81cb26b1</gtr:id><gtr:otherNames>James LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_15138_28_22583928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59ACF89B-7009-4ECA-A657-097335C02AC4</gtr:id><gtr:title>Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42155163bf591934c05740887828b4ac"><gtr:id>42155163bf591934c05740887828b4ac</gtr:id><gtr:otherNames>Shamji MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>ZFAg73cRZPS</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601303</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>